The PREEMPT Act mandates the Secretary of Health and Human Services to provide guidance to states on covering preeclampsia screening and detection.

The PREEMPT Act, or Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act, aims to address the significant health risks associated with preeclampsia, a condition affecting 5 to 8 percent of pregnancies globally. The bill requires the Secretary of Health and Human Services to issue guidance to states on which tests for the early detection of preeclampsia may be covered under the Medicaid program and the Children’s Health Insurance Program. This includes advanced biomarker tests regulated under the Federal Food, Drug, and Cosmetic Act.

The PREEMPT Act mandates the Secretary of Health and Human Services to provide guidance to states on covering preeclampsia screening and detection.

The PREEMPT Act, or Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act, aims to address the significant health risks associated with preeclampsia, a condition affecting 5 to 8 percent of pregnancies globally. The bill requires the Secretary of Health and Human Services to issue guidance to states on which tests for the early detection of preeclampsia may be covered under the Medicaid program and the Children’s Health Insurance Program. This includes advanced biomarker tests regulated under the Federal Food, Drug, and Cosmetic Act.